Back to discover
Disease

Gram-Negative Bacterial Infections

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHGram-Negative Bacterial Infections
4
Publications
10
Clinical trials
1
Related treatments
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Erythrocytes of the common carp are immune sentinels that sense pathogen molecular patterns, engulf particles and secrete pro-inflammatory cytokines against bacterial infection.

Research2024-06-14Frontiers in immunology

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria.

Research2019-11-01Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.

Research2019-11-01Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Research2004-07-15Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Major developments
Upcoming trial readoutHigh impact
A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION
Results expected Q1 20272026-07-01
Major clinical milestoneWorth watching
A Randomized, Double-blind, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of the Drug Fluorothiazinone (Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on Mechanical Ventilation
Primary completion2025-12-31
Clinical Milestones2View
Results expected 1
Recently completed 1
Activity timeline2

Research-associated treatments

Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.

Clinical trials

8 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
10
All trials
2
Active
4
Late-stage
5
Completed
Late-stage studies

Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections

Phase 4 · Completed · National Cancer Institute, Egypt

Multicenter Open-label RCT to Compare Colistin Alone vs. Colistin Plus Meropenem

Phase 4 · Completed · Mical Paul

A Phase 3, Open-label, Noncomparative Study of Tigecycline for the Treatment of Subjects With Selected Serious Infections Due to Resistant Gram-negative Organisms Such as Enterobacter Species, Acinetobacter Baumannii, and Klebsiella Pneumoniae

Phase 3 · Completed · Wyeth is now a wholly owned subsidiary of Pfizer

A Study Comparing Prospective Use of Imipenem/Cilastatin/Relebactam (IMI/REL) to Retrospective Data Using Meropenem/ Vabobactam (MVB) and Ceftazidime/Avibactam (CZA) in Treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae Infections

Phase 4 · Withdrawn · Wake Forest University Health Sciences
Recruiting

A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION

Phase 2 · Recruiting · Pfizer

A Randomized, Double-blind, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of the Drug Fluorothiazinone (Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on Mechanical Ventilation

Phase 2 · Recruiting · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Recently completed

An Open-label Study With a Nonrandomized Single-dose Phase in Subjects With Suspected or Confirmed Aerobic Gram-negative Bacterial Infections Followed by a Randomized, Multiple-dose, Active-controlled Phase in Subjects With Suspected or Confirmed Complicated Urinary Tract Infection (cUTI), Hospital-acquired Bacterial Pneumonia (HABP) or Ventilator-associated Bacterial Pneumonia (VABP) to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Subjects 3 Months to < 18 Years of Age

Phase 2 · Completed · Shionogi

Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections

Phase 4 · Completed · National Cancer Institute, Egypt

Multicenter Open-label RCT to Compare Colistin Alone vs. Colistin Plus Meropenem

Phase 4 · Completed · Mical Paul

An Open-Label, Randomized, Multicenter, Two-Arms Efficacy and Safety Study of 14 Days Treatment With Finafloxacin 400 mg b.i.d. Plus Amoxicillin 1000 mg b.i.d.Versus Finafloxacin 400 mg b.i.d. Plus Esomeprazole 40 mg b.i.d. in Patients With Helicobacter Pylori Infection

Phase 2 · Completed · MerLion Pharmaceuticals GmbH

A Phase 3, Open-label, Noncomparative Study of Tigecycline for the Treatment of Subjects With Selected Serious Infections Due to Resistant Gram-negative Organisms Such as Enterobacter Species, Acinetobacter Baumannii, and Klebsiella Pneumoniae

Phase 3 · Completed · Wyeth is now a wholly owned subsidiary of Pfizer

Research activity

4 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20042024
Most influential

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2004 · 2,962 cites

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019 · 493 cites

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019 · 405 cites

Erythrocytes of the common carp are immune sentinels that sense pathogen molecular patterns, engulf particles and secrete pro-inflammatory cytokines against bacterial infection.

Frontiers in immunology · 2024 · 5 cites
Recent publications

Erythrocytes of the common carp are immune sentinels that sense pathogen molecular patterns, engulf particles and secrete pro-inflammatory cytokines against bacterial infection.

Frontiers in immunology · 2024 · 5 cites

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019 · 493 cites

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019 · 405 cites

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2004 · 2,962 cites
Major themes7
  • Drug Resistance, Bacterial2
  • Aeromonas hydrophila1
  • Carps1
  • Cytokines1
  • Erythrocytes1
  • Fish Diseases1
  • Gram-Negative Bacterial Infections1
Leading journals2
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America3
  • Frontiers in immunology1
Leading researchers8
  • Bischoff T1
  • Chan JTH1
  • Doi Y1
  • Edmond MB1
  • Holzer AS1
  • Klak K1
  • Korytář T1
  • Kyslík J1
Affiliations (unnormalised)6
  • Center for Innovative Antimicrobial Therapy1
  • Doctoral School of Exact and Natural Sciences1
  • Fujita Health University School of Medicine1
  • Institut National de la Santé et de la Recherche Médicale European Unit1
  • Institute for Microbiology1
  • Institute of Zoology and Biomedical Research1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.

Identifiers
MeSHGram-Negative Bacterial Infections
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.